Hydromorphone controlled release - Pain TherapeuticsAlternative Names: PTI 202
Latest Information Update: 14 Oct 2014
At a glance
- Originator DURECT Corporation; Pain Therapeutics
- Developer Pain Therapeutics
- Class Morphine derivatives; Opioid analgesics; Small molecules
- Mechanism of Action Opioid receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Pain